New Propellants, Same Precision: OzUK Brings the Future of pMDIs to Estoril
OzUK is proud to be sponsoring and exhibiting at Respiratory Drug Delivery (RDD) 2025, the leading international conference for inhalation science, held this year from May 11–15 in Estoril, Portugal. You’ll find us at Table 11, ready to talk about how we can support your inhalation product journey; from early formulation to commercialisation.
At OzUK, we specialise in accelerating the development of both innovator and generic pressurised metered dose inhalers (pMDIs). Our expertise in low global warming potential (GWP) propellants—including HFA-152a and HFO-1234ze is unmatched. We offer pilot-scale suspension and solution development, full regulatory support for CTA and IND submissions.
What you’ll see from OzUK at RDD 2025:
Poster Presentation by Daniel Lewis (Senior Scientist) on Plume Temperature Comparisons between legacy (HFA-134a/227ea) and low-GWP propellants (HFA-152a and HFO-1234ze)
Podium Presentation by Dr David Lewis (CSO) on A Priori Formulation Design of solution pMDIs using next-generation propellants
With over 30 years of inhalation development experience, we help clients de-risk and accelerate pMDI programs with scientifically sound, regulatory-ready formulations. Our UK facility includes dedicated fill and test infrastructure for low-GWP propellants, supporting feasibility through to clinical trial supply.
If you’re attending RDD 2025 and developing inhaled medicines, come and speak to the team at Table 11. We’ll be there to discuss your project needs and how we can help bring your product to market faster, smarter, and more sustainably.
More information:
